ArticleCell communication and signaling : CCS2026
Activity-based proteomics analysis revealed that DNJ directly targeted ATP5F1 to alleviate high glucose induced cardiomyocyte injury.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus, characterized by impaired cardiac function and mitochondrial injury. The natural alkaloid 1-deoxynojirimycin (DNJ) has exhibited cardioprotective potential; however, its specific molecular targets in cardiomyocytes are yet to be identified. PURPOSE: This work sought to discover the direct targets of DNJ in cardiomyocytes and elucidate the molecular mechanism behind its cardioprotective activity.
methodsWe first established a cardiomyocyte injury model induced by high glucose. Next, activity-based protein profiling (ABPP) was employed to screen for proteins that directly bind to DNJ. The interactions between DNJ and candidate targets were verified using surface plasmon resonance (SPR), cellular thermal shift assay (CETSA), and molecular docking. Finally, the functional outcomes were validated through small interfering RNA (siRNA) knockdown and plasmid overexpression.
resultsABPP screening identified mitochondrial F0 complex subunit B1 (ATP5F1) as the principal binding target of DNJ. SPR analysis confirmed a high-affinity interaction between DNJ and ATP5F1 (Kd = 52.6 nM). Furthermore, CETSA demonstrated that this binding occurred in living cells. Treatment with DNJ (120 µg/mL) significantly ameliorated high glucose-induced mitochondrial dysfunction, oxidative stress, and apoptosis. Knockdown of ATP5F1 via siRNA attenuated the protective effects of DNJ. Conversely, ATP5F1 overexpression potentiated these protective effects.
conclusionsATP5F1 was identified as a direct functional target of DNJ for the first time. DNJ provides cardioprotection by mitigating mitochondrial malfunction, oxidative stress, and apoptosis via its direct interaction with ATP5F1. These findings collectively clarify a new mode of action for DNJ and offer a scientific basis for its possible therapeutic use in DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.